Company Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
| Country | United States |
| Founded | 2002 |
| IPO Date | May 7, 2015 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 357 |
| CEO | Vikram Karnani |
Contact Details
Address: 100 Technology Center Drive, Suite 300 Stoughton, Massachusetts 02072 United States | |
| Phone | 781 713 3699 |
| Website | collegiumpharma.com |
Stock Details
| Ticker Symbol | COLL |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001267565 |
| CUSIP Number | 19459J104 |
| ISIN Number | US19459J1043 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Vikram Karnani | Chief Executive Officer, President and Director |
| Michael Thomas Heffernan B.S. Pharm, R.Ph. | Co-Founder and Chairman |
| Colleen Tupper | Executive Vice President and Chief Financial Officer |
| Scott Dreyer | Executive Vice President and Chief Commercial Officer |
| Dr. Thomas B. Smith FAAFP, M.D. | Executive Vice President and Chief Medical Officer |
| David Dieter | Executive Vice President and General Counsel |
| Jane Gonnerman | Executive Vice President of Strategy and Corporate Development |
| Dean J. Patras | Chief People Officer |
| Scott Sudduth | Head of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 28, 2025 | ARS | Filing |
| Mar 28, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2025 | 144 | Filing |
| Mar 21, 2025 | 144 | Filing |
| Mar 20, 2025 | 144 | Filing |
| Mar 20, 2025 | 144 | Filing |
| Mar 20, 2025 | 144 | Filing |
| Mar 17, 2025 | 8-K | Current Report |
| Mar 14, 2025 | 144 | Filing |